Camzyos Demonstrates Efficacy, Safety Treating Symptomatic Obstructive Hypertrophic Cardiomyopathy
Results from the Phase III EXPLORER-LTE study found that Camzyos maintained effectiveness in treating symptomatic obstructive hypertrophic cardiomyopathy after 3.5 years of treatment.
